Scholarlink

<p>Lung cancer (LC) is one of the major causes of mortality due to cancer throughout the world, primarily due to difficulties in early detection and the restricted efficacy of conventional therapies. Inhalation drug delivery systems provide a potential strategy for targeted LC therapy by allowing direct deposition of drugs into the lungs, therefore improving therapeutic effectiveness and reducing systemic side effects. This review offers a comprehensive outlook on different inhalation formulations, highlighting their benefits in enhancing drug bioavailability and patient outcomes. It also explores the molecular pathways involved in LC progression and identifies critical LC treatment targets. Although substantial progress has been made in the field of LC treatment, numerous challenges hamper the clinical translation of inhalation therapeutic systems, such as formulation instability, physiological barriers, patient-specific variations, and immune responses. The strategies to deal with these problems are discussed, aiming at the modification of nanocarriers, stimuli-sensitive systems, and immunomodulatory approaches. In conclusion, the review underscores the potential of inhalation systems in the treatment of LC with special emphasis on the promise of personalized medicine and combination therapies to transform LC management.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhalable Therapeutics in Lung Cancer: Overcoming Barriers for Effective Treatment

  • 期刊论文

  • 发表日期：

    2026年3月18日

查看全文
  • Himanshu Paliwal,
  • Tejas Rangbhal,
  • Pratiksha Khedkar,
  • Akanksha Kasture,
  • Pratik Kharche,
  • Sachin S. Gaikwad,
  • Bhupendra G. Prajapati

摘要

Lung cancer (LC) is one of the major causes of mortality due to cancer throughout the world, primarily due to difficulties in early detection and the restricted efficacy of conventional therapies. Inhalation drug delivery systems provide a potential strategy for targeted LC therapy by allowing direct deposition of drugs into the lungs, therefore improving therapeutic effectiveness and reducing systemic side effects. This review offers a comprehensive outlook on different inhalation formulations, highlighting their benefits in enhancing drug bioavailability and patient outcomes. It also explores the molecular pathways involved in LC progression and identifies critical LC treatment targets. Although substantial progress has been made in the field of LC treatment, numerous challenges hamper the clinical translation of inhalation therapeutic systems, such as formulation instability, physiological barriers, patient-specific variations, and immune responses. The strategies to deal with these problems are discussed, aiming at the modification of nanocarriers, stimuli-sensitive systems, and immunomodulatory approaches. In conclusion, the review underscores the potential of inhalation systems in the treatment of LC with special emphasis on the promise of personalized medicine and combination therapies to transform LC management.

Graphical Abstract